

World Heart Federation Roadmap for Heart Failure



João Pedro Ferreira^{*}, Sarah Kraus[†], Sharon Mitchell[‡], Pablo Perel[§], Daniel Piñeiro^{||}, Ovidiu Chioncel[¶], Roberto Colque[#], Rudolf A. de Boer^{**}, Juan Esteban Gomez-Mesa^{††}, Hugo Grancelli^{‡‡}, Carolyn S. P. Lam^{§§}, Antoni Martinez-Rubio^{||||}, John J. V. McMurray^{¶¶}, Alexandre Mebazaa^{###,****,†††}, Gurusher Panjra^{‡‡‡}, Ileana L. Piña^{§§§,|||||}, Mahmoud Sani^{¶¶¶,###}, David Sim^{****}, Mary Walsh^{††††}, Clyde Yancy^{‡‡‡‡}, Faiez Zannad^{§§§§}, Karen Sliwa^{|||||||}

Nancy, and Paris, France; Cape Town, South Africa; Geneva, Switzerland; London, United Kingdom; Buenos Aires, and Cordoba, Argentina; Bucharest, Romania; Groningen, the Netherlands; Cali, Colombia; Singapore; Newtown, New South Wales, and Melbourne, Victoria, Australia; Barcelona, Spain; Glasgow, Scotland; Washington, DC, USA; New York, NY, USA; Kano, Kano State, Nigeria; Indianapolis, IN, USA; and Chicago, IL, USA

In 2012, all Member States of the World Health Organization (WHO) endorsed a historical target to reduce premature mortality from noncommunicable diseases (NCD). This commitment was echoed in 2015 by the United Nations Sustainable Development Goals, which included a target to reduce premature mortality (the measure of unfulfilled life expectancy and deaths between the ages of 30 and 70 years) from NCD by 30% by the year 2030. The Sustainable Development Goals are especially relevant to cardiovascular disease (CVD), the leading cause of death globally, with increasing prevalence in low- and middle-income countries (LMIC).

In support of reaching the Sustainable Development Goals targets, the World Heart Federation (WHF) has undertaken an initiative to develop a series of Roadmaps [1–6] to 1) promote development of national policies and health systems approaches; 2) identify potential roadblocks to effective prevention, detection, and management of CVD; and 3) provide strategies for overcoming roadblocks. These Roadmaps (Figure 1) provide guidance for countries to develop or update national NCD programs, using the framework provided by the WHO Global Action Plan for the Prevention and Control of NCD 2013 to 2020 [7]. The aim of the WHF Roadmap initiative is to drive efforts within national agendas to meet the ambitious targets set out by the UN National Assembly in line with the WHF strategy to translate science into policy and to influence agencies, governments, and policy makers alike.

As care for patients living with heart failure involves the patients, their families, nurses, dietitians, public health experts, general physicians, cardiologists, and dedicated heart failure specialists, the WHF Heart Failure Roadmap is relevant for all professionals caring for patients with this condition. This document aims to provide comprehensive guidance on the complex syndrome of heart failure from a global perspective, by exploring the epidemiology of heart failure, outlining evidence-based therapies that have been shown to improve outcomes [8–10], creating a graphical display of the ideal pathway for heart failure care, identifying

roadblocks, and providing potential solutions for overcoming obstacles to prevention, diagnosis, treatment, and monitoring, in addition to providing recommendations on how to adapt and implement the Roadmap at a national level.

With the overall objective of reducing the burden of heart failure globally, this Heart Failure Roadmap provides WHF Members (including cardiac societies, foundations, and associations) and policy makers with a framework to guide initiatives within their national context, catalyze initial discussions and plan a “call to action,” form Roundtable discussions with key opinion leaders, and leverage support and raise awareness for heart failure.

METHODOLOGY AND SELECTION AND THE EXPERT WRITING GROUP

To ensure a best practice approach and a consensus document (Figure 2), the WHF Heart Failure Roadmap was developed through review of published guidelines and research papers, in consultation with a dedicated writing group composed of experts in heart failure management and health systems research. WHF regional Members were invited to nominate an expert to the writing group to ensure that the content of the Roadmap has true global representation.

An extensive review of the applicability and acceptability of the outlined roadblocks and proposed solutions was conducted. A survey was sent to all WHF Members using snowball sampling to widen the consultation, not only to regional members, but also to national representatives. A total of 146 responses was collated through this process, offering feedback on the proposed Ideal Heart Failure Continuum of Care Pathway (Figure 3) and the presented roadblocks and solutions (Table 1). The results were analyzed, open comments were reviewed and consolidated, and the findings were incorporated into this document.

The development of the Heart Failure Roadmap forms part of a larger global project that seeks to create living documents that inform initiatives in response to the global

The authors report no relationships that could be construed as a conflict of interest.

Supplementary data associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.ghart.2019.07.004>.

From the ^{*}National Institute of Health and Medical Research, Center for Clinical Multidisciplinary Research, University of Lorraine, Regional University Hospital of Nancy, Nancy, France; [†]Groote Schuur Hospital and Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; [‡]World Heart Federation, Geneva, Switzerland; [§]London School of Tropical Hygiene and Medicine, London, United Kingdom; ^{||}Division of Medicine, Hospital de Clínicas Department of Medicine, University of Buenos Aires, Buenos Aires, Argentina; [¶]Institute of Emergency for Cardiovascular Diseases “C.C. Iliescu” Bucharest, University of Medicine and Pharmacy “Carol Davila” Bucharest, Bucharest, Romania; [#]Coronary Care Unit, Sanatorio Allende Cerro, Cordoba, Argentina; ^{**}Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands; ^{††}Cardiology Service, Hospital Universitario Fundación Valle del Lili, Cali, Colombia; ^{‡‡}Cardiology Department, Sanatorio Trinidad Palermo, Buenos Aires, Argentina; ^{§§}Duke-National University of Singapore, Singapore; ^{||||}Department of Cardiology, University Hospital Sabadell Autonomous, University of Barcelona, Barcelona, Spain; ^{¶¶}Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland; ^{###}Université de Paris, Paris,

France; ***U942 MASCOT (cardiovascular MArkers in Stress COnditions), National Institute of Health and Medical Research, France; †††Department of Anesthesia, Burn, Intensive Care, Saint Louis Lariboisière Hospitals, Assistance Publique—Hôpitaux de Paris, Paris, France; ††††Department of Medicine /Cardiology, George Washington University School of Medicine, George Washington University, Washington, DC, USA; §§§Wayne State University, Michigan, USA; |||||Wayne State University, Michigan, USA; ¶¶¶Department of Medicine, Bayero University Kano, Kano, Nigeria; ###Aminu Kano Teaching Hospital, Kano State, Kano, Nigeria; ****Department of Cardiology, Heart Failure Program at the National Heart Center Singapore, Singapore; ††††Department of Heart Failure and Cardiac Transplantation, St. Vincent Heart Center, Indianapolis, IN, USA; †††††Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; §§§§Department of Cardiology, Centre d'Investigation Clinique (CIC), Centre Hospitalier Universitaire, University Henri Poincaré, Nancy, France; and the |||||Hatter Institute for Cardiovascular Research in Africa, Department of Cardiology and Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. Correspondence: K. Sliwa (karen.sliwa-hahnle@uct.ac.za).

GLOBAL HEART
© 2019 World Heart Federation (Geneva). Published by Elsevier Ltd. All rights reserved.
VOL. 14, NO. 3, 2019
ISSN 2211-8160/\$36.00
<https://doi.org/10.1016/j.heart.2019.07.004>

needs of patients with CVD. Using publication as a first step in organizing and establishing consensus on the heart failure “care gap,” the WHF Heart Failure Roadmap can be used as a springboard to initiate a call for action and prescribe measurable steps toward a common goal, at national and international levels.

HEART FAILURE DEFINITION

“Heart failure is a complex clinical syndrome caused by any cardiac structural and/or functional abnormality that results in impairment of ventricular filling or ejection of blood” [9].

Heart failure can present acutely or as a progressive disease characterized by worsening shortness of breath, coughing or wheezing, tiredness and fatigue, fluid retention with swelling of the legs and/or abdomen, and/or reduced ability to do physically demanding tasks or exercise [8].

Central to diagnosing heart failure is the demonstration of underlying structural and/or functional cardiac abnormalities. Accepted definitions used to categorize heart failure include [8,9]: heart failure with reduced ejection fraction ([HFrEF]; left ventricular ejection fraction [LVEF] <40%); heart failure with preserved ejection fraction (LVEF ≥50%); and heart failure with midrange ejection fraction (LVEF 40% to 49%). Patients with heart failure with preserved ejection fraction often have history of hypertension and/or atrial fibrillation [10], whereas patients with HFrEF are often younger and may have a history of ischemic heart disease or cardiomyopathy (Online Tables 1 and 2) [11–15].

RELEVANCE OF HEART FAILURE TO THE GLOBAL BURDEN OF CVD

It has been estimated that there are approximately 26 million cases of heart failure worldwide [15]. This does not account for the cases of heart failure that are undiagnosed or misdiagnosed and, therefore, a true estimate of the global burden heart failure remains unclear [16]. Mortality rates for heart failure patients remain high with 17% to 45% of deaths occurring within 1 year of diagnosis—with the majority of deaths occurring within 5 years of admission [8].

Of the annual 17.9 million cardiovascular-related deaths worldwide, 80% occur within LMIC [15,17–19], a trend replicated in heart failure where mortality rates are higher in these regions [18–21]. Despite this, our understanding of heart failure is largely based on studies undertaken in high-income countries and building a picture that truly reflects the epidemiology of heart failure across all regions, especially LMIC where mortality risk and specific death causes from heart failure are still largely unexplained [17], remains a challenge.

The few data available clearly show that the prognosis in heart failure varies according to geographic area [8]. One-year death rates in patients with heart failure remain high in LMIC, reaching 34% in Africa, 23% in India, 15% in South East Asia, 9% in South America, and 7% in China [17]. Disparities in patient outcomes may be explained by differences in the severity of heart failure at presentation, available therapies, resources, and health care systems [20]. However, further analysis of specific causes of death and related comorbidities is needed to improve patient care.

Numerous causes of heart failure have been described including infectious diseases (Chagas and rheumatic heart disease) and cardiac conditions (hypertension, heart muscle disease, coronary heart disease, valve disease, congenital heart disease, pericardial disease, cor pulmonale, and rhythm disorders) [8]. Figure 4 highlights the most common causes contributing to heart failure by region [17,22,23]. It is evident from this regional map that ischemic heart disease and hypertension are the most common causes of heart failure globally.

SUMMARY OF HEART FAILURE MANAGEMENT GUIDELINES

To prevent the development of the heart failure syndrome, one needs to address its most common causes (e.g., hypertension, ischemic heart disease, rheumatic heart disease) and, ideally, should consider screening for asymptomatic left ventricular (LV) dysfunction in high-risk individuals (Online Table 2) [8,11–15].

The goals of heart failure management are to 1) treat the underlying cause; 2) improve clinical status, functional capacity, and quality of life; 3) prevent hospitalizations; and 4) reduce mortality. Drug therapy for the treatment of the clinical syndrome of heart failure includes diuretic agents to relieve the signs and symptoms of congestion and disease-modifying therapies, such as angiotensin-converting enzyme inhibitors (or angiotensin receptor blockers), beta-blockers, mineralocorticoid receptor antagonists, angiotensin-receptor-neprilysin inhibitor, and ivabradine. These drugs have been shown to reduce hospitalization and improve survival when used as specified by the guidelines [8,9]. Additional therapies, such as hydralazine-isosorbide dinitrate and digoxin, may be used in symptomatic patients with HFrEF. Device therapy (e.g., cardiac resynchronization therapy, implantable cardioverter-defibrillators, LV assist devices) and heart transplantation may be indicated in selected patients with advanced disease. Table 2 represents a summary of heart failure guidelines from European Society of Cardiology and American College of Cardiology/American Heart Association.

CARE GAP AND THE IDEAL HEALTH CARE JOURNEY FOR HEART FAILURE

The “care gap” refers to the difference between optimal, evidence-based, guideline-recommended care and what is

delivered in practice. Although the care gap may be considered larger in LMIC, disparities have been reported in screening, diagnosis, treatment, and monitoring of patients across all income settings. The ideal pathway of care (referred to in this Roadmap as the “continuum of care pathway”) was developed using an evidence-informed approach and considers the entire journey of the patient and a best-practice treatment approach.

The Ideal Journey for Heart Failure Patients

Each step along the heart failure journey is important, with many shared determining factors, regardless of local and regional differences in resources or health service delivery. The continuum of care focuses on a common pathway for heart failure patients (Figure 3) and includes identifying individuals at risk, diagnosing heart failure, outlining necessary investigations, treatment initiation, and follow-up. The aim of this section is not to reiterate published guidelines, but rather to investigate best-practice approaches for each step in the care pathway and to identify important stakeholders that may strengthen health care delivery to patients with heart failure.

Heart Failure Prevention. *General Population:* There is considerable evidence that the onset of heart failure may be delayed or prevented through interventions aimed at modifying risk factors, as outlined in previously published WHF Roadmaps (Figure 1) [1–6]. Heart failure prevention strategies (Figure 3) are not dissimilar to those across the spectrum of CVD, and it is, therefore, appropriate to dedicate time and effort on key primary prevention strategies such as smoking cessation [21,24], alcohol reduction or cessation [25], exercise training [26], as well as secondary prevention measures, as described in previous Roadmaps.

Opportunistic Screening and Diagnosis. *Individual at Risk:* Screening plays an essential role in the early diagnosis of heart disease and is useful in identifying those at higher risk of developing heart failure. Screening needs to be adapted according to affordability and availability of a health care system and the different underlying causes per region. Globally underlying causes of heart failure include hypertension (the most common cause of heart failure), myocardial infarction, diabetes, and valvular heart disease, including rheumatic heart disease and cardiomyopathies [27–29]. In addition to those with traditional CVD risk factors, individuals at increased risk of developing heart failure include peripartum women, those who have received chemotherapy, individuals with systemic inflammatory conditions, and those with a positive family history of heart disease or sudden cardiac death (Figure 3).

Regional and national guidelines in acute and chronic heart failure offer quality recommendations in the diagnosis and management of heart failure, yet for a number of reasons including poor adherence and health economic factors, these recommendations lead to a gap between

best-practice recommendations and implementation [8]. Careful history taking, systematic clinical examination, and appropriate investigations are necessary to follow a best-practice approach [9]. A woman’s pregnancy history is an integral part of her assessment and pregnancy-related diagnoses, such as pre-eclampsia, eclampsia, or gestational diabetes, could signal premature development of CVD with a 4-fold risk of incident heart failure [30].

Despite resource limitations, a diagnosis of heart failure can be made at the primary care level. Careful assessment of symptoms (breathlessness, ankle swelling, and fatigue) and signs (elevated jugular venous pressure, pulmonary crackles, and peripheral edema) can be helpful, but may not be sufficient to confirm a diagnosis of heart failure [8]. The electrocardiogram (ECG) is widely recognized as having an essential role in the diagnosis of underlying cardiac disease [8,9], and, whereas an abnormal ECG has low specificity [31], heart failure is highly unlikely to be present if the ECG is completely normal [32]. Basic investigations, including biomarkers (B-type natriuretic peptide, N-terminal pro-B-type natriuretic peptide), ECG, and focused point-of-care echocardiogram, are useful tools for screening high-risk individuals and confirming a diagnosis of heart failure and, ideally should be accessible at primary care facilities. Future artificial intelligence-enabled “smart” tools for both ECG [33] and echocardiography [34] may further enhance early detection of heart failure at the community level. Patients diagnosed with heart failure usually require referral to higher levels of care for more comprehensive clinical evaluation and investigation, particularly those with advanced disease, to confirm and manage the underlying cardiac condition. A table of diagnostic investigations can be found in Online Table 2 [8,11–15].

Treatment: Initiation of Guideline-Based Therapy and/or Treatment of the Specific Cause.

New-onset heart failure requires urgent initiation of therapy [35]. Heart failure management requires the use of: 1) a guideline-based approach with pharmacological and/or nonpharmacological therapies [9]; 2) a patient-centered approach promoting shared decision making with patients [36]; and 3) patient education to improve treatment adherence [37]. Regardless of whether a patient presents with asymptomatic LV dysfunction or overt heart failure, careful consideration of their history and examination is required to implement an appropriate guideline-based treatment plan [8] (Figure 3, Table 2, Online Table 3).

Heart failure is a clinical syndrome, and a comprehensive diagnosis is dependent on the demonstration of an underlying cardiac cause to ensure appropriate and specific treatment [8]. The diagnostic work-up of the underlying cardiac cause should therefore be conducted in conjunction with the therapeutic management of the heart failure syndrome. Furthermore, to provide holistic care to heart failure patients, other medical and social cofactors, such as concomitant comorbidities, contraception, vaccination,




FIGURE 1. The WHF roadmap initiative. CVD, cardiovascular disease; NCD, noncommunicable diseases; WHF, World Heart Federation.




FIGURE 2. The design and methodology framework. WHF, World Heart Federation.

nutrition, work, driving, and transportation, need to be addressed simultaneously.

Monitoring and Follow-Up: Stable Patient Follow-Up as per Guidelines. Monitoring and follow-up are an essential part in the overall management of heart failure and are discussed in detail in the published guidelines (see Figure 3). The primary goal in monitoring and follow-up is to detect possible decompensation (worsening heart failure) and prescribe appropriate therapy as early as possible. This may be achieved through consultation in a health care facility, via telephone or, more recently, through the use of mobile health (mHealth) packages [38].

PERSPECTIVES ON HEART FAILURE

Heart failure is a chronic, progressive condition with a poor prognosis if left untreated [39]. For the purpose of this Roadmap, barriers and possible solutions to care will be presented from the perspective of: 1) patients, families, communities, patient organizations, and civil society; 2) health care professionals, including clinicians and allied health professionals; and 3) decision makers, nonprofit organizations, government officials, and leaders in heart failure.

Heart failure can be a life-changing and debilitating disease [40]. The diagnosis may lead to inaccurate assumptions and misconceptions about the condition [41–43]. The gradual decline of patients with heart failure, often interrupted by episodes of acute deterioration, recurrent hospitalizations, or sudden unexpected death can have devastating effects on both patients and their families [44].

"A lot of people with heart failure think that's the end of their lives, as soon as they get a diagnosis. I did at first, I thought, that's it." "With heart failure it's very unknown, people just don't know what it is" [45].

Differences in perspectives between patients and health care professionals may affect patient care. One study reported that patients and caregivers believed that "trouble breathing" was a reason for hospitalization, whereas clinicians identified nonadherence to diet and medications, progression of disease, and various socioeconomic factors, such as a lack of social support and access to medications, as reasons for hospital admissions. The investigators suggest that health care workers may not recognize some of the biggest challenges facing heart failure patients [46]. The *Handbook of Multidisciplinary and Integrated Heart Failure Care* supports a patient-centered-care approach that is flexible and adaptable to the patients' needs [47] (Figure 5). The purpose of this Roadmap is to propose strategies and interventions to improve the care of patients with heart failure across all settings. A unified approach to care requires an improved understanding and appreciation of the daily challenges faced by patients and caregivers, dedicated funding, and well-designed health systems that meet the specific needs of these patients.




FIGURE 3. Ideal HF continuum of care pathway. BMI, body mass index; BNP, B-type natriuretic peptide; BP, blood pressure; CMR, cardiac magnetic resonance; CRT, cardiac resynchronization therapy; CTA, computed tomography angiography; CXR, chest x-ray; ECG, electrocardiography; HIV, human immunodeficiency virus; HF, heart failure; HR, heart rate; ICD, implantable cardioverter-defibrillator; LVAD, left ventricular assist device; QOL, quality of life; SCD, sudden cardiac death; TOE, transoesophageal echocardiography.

TABLE 1. Roadblocks and solutions

Level	Roadblocks	Potential Solutions
Prevention of Heart Failure		
Patient factors	Lack of patient education and awareness Lack of affordability of healthier lifestyle choices and therapies to address risk factors	Develop public awareness programs about risk factors and HF Implement community-based healthy living programs
Health care workers	Lack of education and/or training among physicians about the importance of HF screening and prevention Physician apathy and/or lack of incentive	Improve HF awareness among health care professionals Address risk factors for CVD using WHF Roadmaps and published guidelines—emphasis on identifying individuals at risk and preventative strategies
Health care systems	Lack of patient education programs Environmental barriers to lifestyle modification Lack of training initiatives for health care workers Lack of country-specific protocols for screening Lack of, or inadequately supported, screening programs—staff, equipment, space	Engage at government level between sectors to address education and environmental barriers Subsidize training initiatives Develop region-specific protocols for screening Provide government-subsidized screening programs
Diagnosis of Heart Failure—Factors That Delay Diagnosis and Result in Delayed Treatment Initiation		
Patient factors	Limited access to health care facilities with sufficient expertise to diagnose HF Affordability of specialized investigations Late presentation due to socioeconomic status, poor education, or rural isolation Patient fears, social implications, and stigma of having a diagnosis of HF	Standardize costs for investigation, lobby for government-driven cost subsidies for essential diagnostic investigations Engage across multiple sectors to improve socioeconomic status, education, living conditions, road access, transportation services Engage in the community to improve patient awareness and education
Health care workers	Lack of education and training among physicians about HF diagnosis and treatment Lack of downstream support from specialist services to facilitate referral	Improve awareness of diagnostic criteria and clinical practice guidelines Facilitate interaction between primary level health care workers and specialists
Health care systems	Resource limitations at the various levels of care Lack of the appropriate tests/equipment to make a HF diagnosis—ECG, echocardiogram, natriuretic peptide Lack of funding for experienced and/or qualified staff	Provide access to investigations necessary to diagnose or exclude HF at a primary care level—e.g., natriuretic peptide, point-of-care echocardiography Implement health care worker outreach programs Establish referral protocols to ensure equity of care—accessibility to diagnostic services
Treatment of Heart Failure—Accessibility and Affordability of Therapies		
Patient factors	Out-of-pocket expenditure for medications, hospitalization, or intervention Adherence on treatment Failure to attend follow-up—travel time and transport cost, leave from work, lack of child-care services, impaired mobility due to advanced disease Patient fears and lack of understanding about HF treatment Advanced disease at presentation due to late presentation to health care facility	Ensure availability of application for disability compensation, if appropriate, and engage with employers Address adherence to treatment Disseminate patient education (pamphlets, waiting room education initiatives, nurse-driven counseling) to improve patient awareness Promote patient-driven HF associations and family and/or community engagement

(continued)

TABLE 1. Continued

Level	Roadblocks	Potential Solutions
Health care workers	<p>Clinician inexperience and lack of adherence to guidelines</p> <p>Poor tolerability of drugs due to inadequately treated congestion, side effects, or rapid titration</p> <p>Management challenges related to persistent congestion</p> <p>Inadequate dosing of diuretic therapy, poor absorption of oral diuretics, diuretic resistance</p> <p>Reduced renal perfusion and/or renal impairment</p> <p>Failure to optimize drug therapies directed at neurohormonal activation (RAAS)</p> <p>Failure to titrate doses of medical drug therapies</p> <p>Infrequent follow-up</p> <p>Failure to identify and manage precipitating factors (e.g., anemia) and comorbidities</p> <p>Failure to identify and treat underlying cause of HF</p> <p>Failure to refer patients for advanced HF therapies (e.g., drug therapies, devices, transplant, surgery, percutaneous intervention)</p> <p>Lack of knowledge about available services for advanced HF care</p>	<p>Offer periodic training of health care professionals</p> <p>Provide summarized guideline-based protocols to assist clinicians in practice</p> <p>Disseminate clinician education on drug therapy side effects, titration protocols, red flags, monitoring (e.g., digoxin toxicity)</p> <p>Develop problem-based training initiatives for doctors and nurses</p> <p>Dosing of diuretic agents and use of combination diuretic therapy</p> <p>Indications for hospitalization for IV diuresis (\pminotropes)</p> <p>Monitoring of renal function and management of renal impairment in HF</p> <p>Introduction and titration of disease-modifying therapies</p> <p>Counsel patients regarding adherence, potential drug side effects, fluid and salt restriction, weight-guided adjusted diuretic therapy</p> <p>Establish nurse-run clinics for follow-up</p> <p>Standardize investigations in HF at different levels of care, aimed at identifying etiologies, precipitating factors, and comorbidities</p> <p>Develop referral protocols specific to local resources and services to facilitate appropriate referral</p>
Health care systems	<p>Lack of availability of essential medications</p> <p>Lack of affordability of essential medications</p> <p>Lack of monitoring of drug quality</p> <p>Lack of standardized procurement protocols</p> <p>Pharmacy administrative challenges and stock-outs</p> <p>Lack of appropriately trained pharmacists</p> <p>Lack of advanced HF specialist services</p> <p>Lack of surgical and percutaneous intervention expertise and/or facilities</p> <p>Lack of rehabilitation services</p> <p>Lack of palliative care programs</p> <p>Prolonged waiting periods related to service delivery</p>	<p>Create a national EDL listing of essential medications</p> <p>Ensure availability of EDL-listed drug therapy</p> <p>Implement quality assurance strategies</p> <p>Implement cost-reducing strategies—development and procurement of generic therapies, standardization of drug costs, tendered procurement of drugs</p> <p>Lobby for government-subsidized care</p> <p>Develop HF-specific services at various levels of care</p> <p>Develop industry-related initiatives to reduce costs of devices and equipment</p> <p>Encourage private fundraising initiatives</p> <p>Collaborate with NGO and government</p> <p>Invest in HF-directed research initiatives—directed at new and affordable therapies, evidence-based health care performance measures, cause and effect</p> <p>Develop e-health platforms for monitoring</p>

CVD, cardiovascular disease; ECG, electrocardiogram; EDL, essential drug list; HF, heart failure; IV, intravenous; NGO, nongovernmental organization; RAAS, renin-angiotensin-aldosterone system; WHF, World Heart Federation.

ROADBLOCKS AND SOLUTIONS

This section of the WHF Heart Failure Roadmap has been developed in consultation with WHF Members who were offered the opportunity to comment, via a WHF survey, on proposed roadblocks and solutions relevant to their specific contexts. WHF Members were asked to comment on the following: 1) the setting for care; 2) the roadblock(s)

and evidence; 3) an integrated approach to specific solutions; and 4) examples of initiatives that have been implemented in practice. A summary of the identified roadblocks and possible solutions is presented in [Table 1](#). The WHF survey, rolled out using the snowball sampling method, gathered >100 responses regarding key questions linked to the proposed ideal pathway of care for heart




FIGURE 4. Most common causes of HF geographically. HHF (Hospitalized Heart Failure) Registries include ADHERE (Acute Decompensated Heart Failure National Registry); ADHERE-AP (Acute Decompensated Heart Failure National Registry International—Asia Pacific); AHEAD (Acute Heart Failure Database); ALARM-HF (Acute Heart Failure Global Registry of Standard Treatment); ATTEND (Acute Decompensated Heart Failure Syndromes); EFICA (Epidémiologie Française de l’Insuffisance Cardiaque Aigüe); EHFS II (European Heart Failure Survey II); ESC-HF (European Society of Cardiology—Heart Failure); GW TG-HF (Get With The Guidelines—Heart Failure); IN-HF (Italian Registry on Heart Failure); OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure), RO-AHFS (Romanian Acute Heart Failure Syndromes); THESUS-HF (The Sub-Saharan Africa Survey of Heart Failure) [22], INTER-CHF (International Congestive Heart Failure) [17], Hunter HF [23]. AF, atrial fibrillation; HD, heart disease.

failure. Information gathered from this survey has enabled us to focus on high priority areas and to include specific examples of interventions and evidence in practice.

Note: Within this section not all roadblocks and solutions are discussed. The focus has been targeted on the areas that received highest levels of agreement within the WHF survey results from April 2019, with support from reported roadblocks from published findings.

Screening and Early Diagnosis

Setting: General Public and Civil Society.

A “low level of understanding among patients with heart failure” was the highest ranked perceived roadblock in early diagnosis; almost 48% of survey respondents cited this as the highest, or second highest, priority area in the prevention of heart failure in the general population. In addition, a well-noted barrier in both the published reports and the WHF survey, was “a low level of awareness and knowledge on symptoms of heart failure among health care professionals, particularly at primary care level” [42], and “the general public” (SHAPE [Study Group on HF Awareness and Perception in Europe] study) [48,49]. More recent studies reiterate that awareness of heart failure has not improved in the past 10 years, despite a rising incidence of heart failure worldwide, with a reported lifetime risk of 1 in 5 [50]. Low awareness of the symptoms associated with heart failure in communities may delay the presentation of patients to a health care facility, potentially

postponing diagnosis and treatment. Heart failure has and continues to be fraught with misunderstandings, inaccuracies, and misconceptions [43].

Possible solutions to overcome low awareness of heart failure requires local, national, regional, and international efforts to improve the public’s understanding of heart failure using all possible communication channels and community-based healthy living programs. The website www.heartfailurematters.org is a useful and easy-to-access source of information for patients, families, and caregivers, and is translated into 9 languages [51]. European Heart Failure Awareness Week, Heart Failure Awareness Week—“Do Your Part, Know Your Heart” Campaign (Heart Failure Society of America) and “Keep it Pumping” Campaign (Cardiology Society of India) are examples of programs designed to create awareness among patients and caregivers and gather the support of national societies. Whereas evidence is lacking in the effectiveness of awareness campaigns in heart failure specifically, research in other disease areas indicates that increased awareness directly correlates with earlier detection and diagnosis [52,53]. The key action area is to create open, direct, and innovative communication opportunities that all people involved in the global fight against heart failure can actively support.

Screening

Screening patients for asymptomatic LV systolic dysfunction, risk of heart failure, or minimal symptoms such as

TABLE 2. Summary of HF treatment guidelines

	ESC 2016 (Evidence Class, Level)	ACCF/AHA 2013/2016 (Evidence Class, Level)
Recommended therapies to prevent or delay the onset of HF ACCF/AHA Stages A and B	Treatment of hypertension (I, A) Treatment with statins in patients with CAD or at high risk of CAD (I, A) ACE-I can be considered in patients with asymptomatic LV dysfunction with or without a prior MI (I, A; I, B). ACE-I can be considered in patients with stable CAD regardless of LVEF (IIa, A) BB in asymptomatic LV dysfunction and prior MI (I, B) Empagliflozin can be considered in DM2 (IIa, B) Lifestyle modification—smoking cessation (I, C), alcohol intake reduction (I, C), other risk factors reduction (IIa, C)	Stage A: Treatment of hypertension and lipid disorders (I, A) Treatment of other conditions—obesity, DM, tobacco use, and cardiotoxic agent avoidance (I, C) Stage B: ACE-I in asymptomatic patients with reduced EF with or without a history of MI or ACS (I, A) and BB in asymptomatic patients with reduced EF with (I, B) or without (I, C) a history of MI and/or ACS Statins in patients with a history of MI and/or ACS (I, A) Treatment of hypertension (I, A)
Diuretics to relieve symptoms and signs of congestive HF ACCF/AHA Stages C and D	Diuretics are recommended to reduce signs and symptoms of congestion (I, B). Loop diuretic agents produce a more intense and shorter diuresis than thiazides. The combination may be used to treat resistant edema	Diuretics are recommended in patients with HFrEF who have evidence of fluid retention to improve symptoms (I, C). Loop diuretic agents are preferred; however, thiazide diuretic agents may be considered in hypertensive patients with mild fluid retention
Recommended first-line OMT for symptomatic HF—see guidelines for details on dose titration ACCF/AHA Stages C and D	ACE-I and BB are recommended in patients with HFrEF (I, A) MRA is recommended for patients with HFrEF who remain symptomatic despite treatment with an ACE-I and a BB (I, A)	ACE-I and BB (bisoprolol, carvedilol, or metoprolol) are recommended in all patients with HFrEF (I, A) MRA is recommended in patients with NYHA functional class II–IV HF with LVEF \leq 35% (I, A), or following an acute MI in patients with LVEF \leq 40% who develop HF or have DM (I, B)—see guidelines for strategies to minimize hyperkalemia
Recommended therapies (where resources allow) in patients with LVEF \leq 35% that remain symptomatic despite first-line OMT ACCF/AHA Stages C and D	ARB can be used in ACE-I-intolerant patients (I, B) Drug therapies: Ivabradine for patients in sinus rhythm with HR \geq 70 beats/min (IIa, B), or in patients unable to tolerate BB (IIb, C) ARNI to replace ACE-I in symptomatic patients (able to tolerate ACE-I or ARB and on OMT) (I, B) Device therapies (only I, A/B recommendations): CRT for symptomatic patients with HF in sinus rhythm and LBBB, with QRS interval \geq 150 ms (I, A), or QRS interval 130 to 149 (I, B). Consider CRT rather than RV pacing for patients with an indication for ventricular pacing and high-degree AV block ICD for patients with LVEF \leq 35% despite OMT (IHD—I, A; DCM—I, B) or history of a VT/VF (I, A) Mechanical circulatory support and transplantation as per guidelines	ARB can be used in ACE-I-intolerant patients (I, A) Drug therapies: Ivabradine may be used in patients in sinus rhythm with HR \geq 70 beats/min, on OMT including maximal tolerate BB dose ARNI may be used in conjunction with a BB and MRA in selected patients with HFrEF (I, B-R) Device therapies (only I, A recommendations listed): CRT for patients with LVEF \leq 35%, sinus rhythm, LBBB, QRS interval \geq 150 ms and Class II to IV (ambulatory) symptoms (I, A for Class III/IV, and I, B for Class II) ICD for primary prevention of SCD in selected patients with LVEF \leq 35% and NYHA functional class II/III symptoms on OMT with an expected survival of $>$ 1 yr (I, A) (at least 40 days post-MI, if present) Mechanical circulatory support and transplantation as per guidelines (Stage D)
Additional therapies for symptomatic patients with HFrEF ACCF/AHA Stage C and D	Digoxin may be considered in patients in sinus rhythm on OMT to reduce hospitalizations (IIb, B) Combination of hydralazine and isosorbide dinitrate can be considered in black patients on OMT (IIa, B), or in patients unable to tolerate ACE-I/ARB (IIb, B)	Digoxin can be given to patients with HFrEF (IIa, B) The combination of hydralazine and isosorbide dinitrate is recommended for African Americans with NYHA functional class III to IV HFrEF receiving OMT with ACE-I and BB (I, A) or in patients who cannot be given an ACE-I or ARB (IIa, B)

(continued)

TABLE 2. Continued

	ESC 2016 (Evidence Class, Level)	ACCF/AHA 2013/2016 (Evidence Class, Level)
Treatments with unproven benefit in symptomatic patients in HFrEF	Statins (unless otherwise indicated); anticoagulation or antiplatelet therapy (unless otherwise indicated); renin inhibitors	Nutritional supplements, hormonal therapies
Treatments that may cause harm in patients with HFrEF	Thiazolidinediones, NSAID or COX-2 inhibitors, diltiazem, verapamil, ARB in combination with ACE-I and MRA, ARNI in combination with ACE-I, CRT is contraindicated if QRS interval is ≤ 130 ms	Verapamil, ARB in combination with ACE-I and MRA, long-term infused positive inotropic agents, ARNI should not be given in patients with a history of angioedema or with an ACE-I (36-h washout period)

ACCF/AHA stages are defined as follows: Stage A as being at high risk but without structural heart disease or symptoms of HF; Stage B as structural heart disease but without signs or symptoms of HF; Stage C as structural heart disease with prior or current symptoms of HF; and Stage D as refractory HF requiring specialized interventions. ACCF, American College of Cardiology Foundation; ACE-I, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; AHA, American Heart Association; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; AV, atrioventricular; BB, beta-blocker; CAD, coronary artery disease; COX-2, cyclooxygenase 2; CRT, cardiac resynchronization therapy; DCM, dilated cardiomyopathy; DM2, diabetes mellitus type 2; ESC, European Society of Cardiology; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HR, heart rate; ICD, implantable cardioverter-defibrillator; IHD, ischemic heart disease; LBBB, left bundle branch block; LV, left ventricular; LVEF, left ventricular ejection fraction; OMT, optimal medical therapy; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NSAID, nonsteroidal anti-inflammatory drugs; NYHA, New York Heart Association; RV, right ventricular; SCD, sudden cardiac death; VF, ventricular fibrillation; VT, ventricular tachycardia.

mild dyspnea is not straightforward and there is no single investigation that can conclusively confirm a diagnosis of heart failure [9]. Evidence continues to emerge for implementing standardized screening for heart failure [54]. Screening of high-risk patients using algorithms such as the SCORE (Systematic COronary Risk Evaluation) Risk Charts or the Framingham risk calculator have reported mixed success [55]. Targeting high-risk populations require effective strategies for identifying at-risk patients within clinical practice [55]. Whereas current guidelines underline the importance of natriuretic peptides for the purpose of early diagnosis of heart failure, evidence is building in support of their use in prevention and screening in high-risk individuals [54–56]. Examples of the use of natriuretic peptides in practice is further discussed within the diagnostic section of this document.

For an integrated approach to improving awareness of heart failure, see Table 3 [54,57,58].

Diagnosis

Setting: Primary Care, Community Care, Specialist Centers.

Making an accurate comprehensive diagnosis requires a range of diagnostic tools and information, in conjunction with clinical judgment and expert knowledge. Whereas the diagnosis of patients presenting with the classic symptoms of heart failure can be relatively straightforward [59], it can be more difficult in the early stages of disease when symptoms and signs may be less obvious, particularly if there is limited availability of the necessary investigative modalities [32]. A number of studies have sought to investigate clinically relevant diagnostic research at the primary care level in the detection of heart failure [60–62] subsequently confirmed following investigations by a cardiologist at a specialist clinic [61].

An Integrated Approach to Address Roadblocks to Diagnosis, Examples in Practice. *Limited investigations at primary care level:* The role of primary care in the detection and diagnosis of heart failure is critical [63]. Disparities in the diagnosis and management of heart




FIGURE 5. An integrated approach to patient care.

failure patients have been reported in various studies worldwide, highlighting the importance of training health care providers within the primary care settings to improve patient outcomes. One example in practice was the launch of the One Simple Blood Test campaign by the Pumping Marvellous Foundation in the United Kingdom to raise awareness among general practitioners on the use of natriuretic peptides testing to facilitate earlier diagnosis of heart failure at the primary care level [64–66]. There are an increasing number of studies that support the use of natriuretic peptides biomarkers in early detection of heart failure [9,65,66].

Improving access to diagnostic tests: Late presentation of heart failure patients (due to poor socioeconomic status, low levels of education or rural isolation) was the highest ranked roadblock related to diagnosis from the WHF survey, with 89% of survey respondents in agreement. Another frequently cited roadblock was access to specialist clinics for diagnosis and management of heart disease. Echocardiography is the single most important diagnostic imaging technique [67], yet 10% to 25% of patients admitted to hospitals in Europe and the United States with a primary diagnosis of heart failure do not undergo echocardiography [68]. Overcoming this barrier requires: 1) the improvement of service delivery models; and 2) upskilling and task shifting of specific skills of health care workers along the care pathway.

For early detection and diagnosis, there is a need to commission cost-effective testing opportunities, most notably for echocardiography [8] and natriuretic peptides [69] to facilitate the diagnosis of heart failure. Both these recommendations are set forth in the 2016 *Focus on Heart Failure* report [70]. It is well recognized that CVD is common in LMIC, and 44% of patients with newly diagnosed CVD present with heart failure [71]. In Africa, a large percentage of the population simply do not have access to the necessary care, with limited access to doctors, particularly specialists residing in capital cities, and have challenges associated with transportation, particularly in rural areas [72].

The following example tells a compelling story of an effort, supported of the Rwandan Ministry of Health, to reach a large at-risk population in Rwanda. With an aim of decentralizing services for heart failure, integrated nurse-led and physician-supervised clinics were set up in 2 rural public-sector district hospitals. A strategy to disseminate the use of portable echocardiography and simplified algorithms for diagnosis was established. Nurses were trained to perform and interpret limited echocardiographic studies using visual qualitative inspection to make a preliminary diagnosis, with a confirmatory diagnosis made following referral to a cardiologist. This simplified approach to early diagnosis in a resource-limited setting is just an example of how to provide care in difficult-to-reach populations [73]. Access to specialist care at a district level can also be achieved by arranging rotational specialist visits and may help to address a number of reported roadblocks along this care pathway.

For an integrated approach to improve access to diagnostic tests, see Table 4 [74,75].

Treatment

Setting: Specialist centers, primary care, community care centers, home care visits.

The aim of heart failure treatment is to improve life expectancy and quality of life [76]. Within the pathway of care, initiation of treatment and therapeutic strategies for heart failure patients varies considerably depending on the cause of heart failure. Patients with asymptomatic LV systolic dysfunction may follow a treatment pathway that differs considerably from the approach for patients with overt heart failure following a cardiac event [9]. Determining the primary diagnosis can be particularly challenging in patients with multiple cardiovascular and noncardiovascular comorbidities, and diagnostic uncertainty may sometimes delay the implementation of appropriate treatment strategies. Treatment pathways may vary depending on disease severity, the underlying cause, and the classification (HFrEF, heart failure with midrange ejection fraction, or heart failure with preserved ejection fraction) of heart failure and may involve non-pharmacological, pharmacological, and invasive (percutaneous or surgical) interventions [8]. In *Disease Control Priorities, Third edition*, chapter 10, “Heart Failure,” offers a summary report of heart failure interventions applicable across geographic settings [77].

Medication may help to slow disease progression, improve symptoms, and decrease hospital readmissions in heart failure patients [76,78], yet adherence to medication remains among the greatest perceived barriers to care among health care professionals and researchers in cardiovascular health [79–81]. This perception was reflected in the WHF survey to Members with “adherence on medication” reported as the greatest barrier (over 90% agreement) to best-practice treatment. Additional barriers include a low level of knowledge among patients about the medication they are prescribed [82], and prescribed treatment may not be in alignment with published guidelines and evidence-based therapy [83].

An Integrated Approach to Address Roadblocks to Treatment, Examples in Practice.

There are a number of trials and studies that support the positive effect of patient interventions pre-discharge and at 60 and 90 days following hospital admission, particularly with regard to medication adherence (IMPACT-HF [Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure] trial [84]; BRING-UP [Beta-blockers in Patients With Congestive Heart Failure: Guided Use in Clinical Practice] [85]; OPTIMIZE-HF [Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure] [86]). To design targeted interventions, better understanding about the factors that lead to poor adherence to medications from the patient and

TABLE 3. An integrated approach to improving awareness of heart failure

Target	Roadblock	Possible Solutions
Patients, carers, families, patient organizations, and civil society	Lack of awareness and lack of knowledge of heart failure	Support patient organizations to <i>communicate</i> with the general public, patients, and caregivers by providing the information they need to empower patients to make informed decisions on seeking treatment, identifying risks, and playing a role in the management of their own health.
Patients, carers, families, patient organizations, and civil society		Harness <i>advocacy</i> as a powerful tool to bring together those with a common cause to raise the profile of heart failure on national agendas, thereby raising awareness of heart failure among patients, but also among decision and policy makers.
Leaders in cardiovascular health		Strengthen <i>leadership</i> among policy and decision makers, so they better recognize and understand the challenges of heart failure care. Policy continues to fail in making the essential link between scientific evidence to set policy decisions.
Leaders in cardiovascular health		Drive <i>action among leaders</i> to reduce inequalities across geographic settings. Strengthen <i>communication</i> across sectors to ensure alignment in strategies from national to urban and rural settings with a view to putting heart failure on national priority agendas.
Health care workers (primary and secondary care setting)		Work <i>collaboratively</i> with patients to reduce their risk of developing heart failure and help them to manage their health. Build <i>evidence</i> on the use of natriuretic peptide-based screening and collaborative care.
Evidence in Practice		
PAHO Rallies New Partners for Chronic Disease Prevention: the Pan American Health Organisation (PAHO) brought together health advocates across the continent to become partners in a public-private effort to fight NCD focusing on key actions areas including changing policy, reducing risk factors, and improving treatment.		
“Policy makers’ perceptions of the high burden of heart disease in rural Australia” [57]: a paper highlighting inequality in resourcing, and political pressure and education as key constraints to evidence-based policy in rural communities.		
Pan African Ministries of health meeting on hypertension: an example of a regional meeting involving ministries of health, education, agriculture, transport and finance, among other stakeholders, to support a move from science into policy and to leverage support for key recommendations in addressing hypertension in Africa [58].		
STOP-HF (Natriuretic peptide-based screening and collaborative care for heart failure) randomized study: the first reported example to show a reduction in newly diagnosed heart failure, suggesting that a targeted strategy for the prevention of heart failure using natriuretic peptides and collaborative care in a community population may be effective [54].		
NCD, noncommunicable diseases.		

community perspective is required. Studies for other chronic conditions, such as the antiretroviral qualitative study in human immunodeficiency virus (HIV) conducted in South Africa [87], provide valuable insights into population-specific challenges related to adherence.

The economic burden of heart failure, particularly the cost related to hospitalizations, has generated research interest into the various models of care that may improve outcomes, particularly rehospitalization [88]. Several studies have successfully shown the importance of community-based programs in improving patient adherence to medication [80,89] and reducing hospitalization [90]. In an effort to improve medication adherence for antiretroviral therapy in HIV, Antiretroviral Therapy Clinics in South Africa have introduced a “dual solution approach.” This approach focuses on pairing up “community-based patient follow-up programs and patient education” initiatives (discussed in more detail in the Monitoring section) on key messages and specific information considered essential for patients to manage their disease.

For other possible solution focused on treatment, see Table 5 [89,91–94].

Monitoring

Setting: Primary care, community care centers, home care visits, specialist centers.

Heart failure monitoring refers to the follow-up of patients to detect and treat the signs and symptoms of heart failure to prevent disease progression. Recurrent hospitalizations are common in heart failure [8,9] and may be a consequence of disease progression, suboptimal treatment, a lack of psychosocial support, poor diet and/or impaired capacity for overall self-care [92,95]. A collaborative multidisciplinary approach is often required to reduce hospital readmissions and improve quality of life [96,97]. A lack of knowledge of the purpose of medications and how to self-manage symptoms of deterioration [98,99] was the highest reported roadblock to best patient care. Furthermore, a limited understanding of heart failure among patients and caregivers is

TABLE 4. An integrated approach to improve access to diagnostic tests

Targeted at	Roadblocks	Possible Solutions
Patients, carers, families, patient organizations, and civil society	Lack of access to primary care clinics for diagnosis	Implement patient <i>communication</i> and <i>education</i> initiatives that are essential to deliver best-practice care to heart failure patients. Early detection and diagnosis are uniformly linked to awareness and prevention. Recognizing the signs and symptoms of heart failure, understanding specific risk factors, and communicating with health care professionals is an essential step.
Leaders in cardiovascular health	Lack of knowledge among the general public to recognize symptoms and seek medical attention	Improve access for patients to overcome social inequalities and late presentation due to poor education or rural isolation. Invest in <i>leadership and agency in health system planning</i> to set up decentralized heart failure clinics linked to centralized advanced treatment centers.
Health care workers (primary and secondary care setting)		Support patients with low health literacy using e-health in a collaborative approach to care. Appoint experts to lead heart failure <i>care and advocacy</i> across settings and disciplines. This is an evidence-based consensus policy recommendation that focuses on an integrated approach to care to develop protocols, training and local auditing [74].
Evidence in Practice		
Decentralized heart failure centers established linked to a centralized care unit across South India to improve access for patients: this intervention has yet to be published but was shared with WHF during the survey process.		
HeLP-GP (Health eLiteracy for prevention in General Practice) intervention from Australia [75]: this study investigates the impact and outputs of a mobile health application for adults with lower levels of health literacy in the primary care setting.		
WHF, World Heart Federation.		

reflected by reports of poor correlation between symptoms, such as breathlessness, and the disease itself [44,45,98].

An Integrated Approach to Address Roadblocks to Monitoring, Examples in Practice. *Patient education:* Educating patients is central to patient care and has been shown to improve patient outcomes and quality of life

[99,100]. There are numerous approaches to patient education, and consideration of different learning styles in the dissemination of key messages is essential when choosing an approach. The use of blended learning and a multimethod approach tailored to patient needs may be required [101,102]. In addition, follow-up programs must consider the most appropriate intervention for each patient according to their specific needs [103]. The

TABLE 5. Other possible solutions focused on treatment

Targeted at	Roadblock	Possible Solutions
Patients, carers, and health care professionals	Lack of medication adherence	Encourage informed decision making with patients and carers. Equip patient education initiatives with behavioral supports to improve medication adherence. Implement patient education programs and interventions to support treatment adherence.
Leaders in cardiovascular health		The treatment of patients with a polypill that is affordable [91] is well reported to improve adherence. This solution could well be adapted for heart failure [92]. Policy interventions that reduce direct costs to patients for prescriptions through reduced medication copayments or improved prescription drug coverage have been shown to improve adherence to medication.
Health care workers (primary and secondary care setting)		Take a collaborative approach to care that has been shown to systematically improve adherence to medications.
Evidence in Practice		
World Health Organization and Sri Lanka study: underlines effectiveness and safety of treating patients with a polypill [93].		
Copayment reductions: generate greater medication adherence in targeted patients 2010 [94].		
Pharmacist intervention to improve medication adherence in heart failure: a randomized trial 2007 [89].		

TABLE 6. An integrated approach to improving patient monitoring and follow-up

Targeted at	Roadblock	Possible Solution
Patients, carers, families, patient organizations, and civil society	Lack of follow-up programs for patients	Improve health literacy among patients through targeted programs. <i>Education</i> for self-care through follow-up programs has been shown to have a positive impact on reduced mortality and reduced hospitalization.
Leaders in cardiovascular health	Lack of collaboration across care settings	Implement education and capacity-building programs for health care professionals at primary and community care level as a first-line approach to improving monitoring and follow-up of patients.
Health care workers (primary and secondary care setting)		Implement interventions and follow-up treatment programs, including mHealth and e-health interventions. Where this may be difficult to achieve telephone support services have also shown better self-care behavior.
Evidence in Practice		
<p>CardioMEMS heart failure system (Abbott, Abbott Park, Illinois), which measures the pulmonary artery pressure and heart rate through an implanted sensor: daily blood pressure readings transmit data to either a primary care or specialist doctor supporting continuous monitoring [107].</p> <p>“Effect of a medication-taking behavior feedback, theory-based intervention on outcomes in patients with heart failure” 2011 [108].</p> <p>DIAL (Randomised trial of telephone intervention in chronic heart failure) trial, which tested the effectiveness of a telephone-based intervention covering more than 50 centers and 1,500 patients: highlighted the positive impact of this follow-up program to reduce heart failure hospital admissions by 30% [106].</p>		

mode of delivery of education may vary depending on the setting, the health care team, and how civil society organizations deliver key disease messages. Educational frameworks and design methodology are essential considerations in implementing effective education programs [104].

Disease management: A recent Cochrane review evaluated the role of disease management for patients with heart failure. Disease management refers to a model of care that emphasizes proactive and preventive care in hospitals, clinics, or homes, rather than crisis intervention as per the traditional model. These models are typically run by nurses and/or multidisciplinary teams. Data from 47 randomized clinical studies (10,869 participants) suggested that case management and multidisciplinary interventions may reduce all-cause mortality; however, there is limited evidence that disease management decreases hospital readmissions or heart failure–related deaths. Although promising, the overall quality of evidence is low and most of the studies related to disease management have been conducted in high-income countries [105].

Telemonitoring: Another recent Cochrane review evaluated the role of noninvasive home telemonitoring and telephonic support for people with heart failure [106]. The review identified 41 randomized controlled trials: 25 studies (9,332 participants) evaluating telephonic support, and 18 evaluating telemonitoring (3,860 participants). Only 2 studies evaluated both interventions and most of the studies were conducted in high-income countries. There was moderate evidence that home telemonitoring or telephonic support reduces all-cause mortality and hospitalization due to heart failure.

Whereas interventions such as education, multidisciplinary teams, disease management, and technology for

monitoring are promising, their implementation and sustainability in real-world settings remain a challenge. Further implementation research is needed to fully understand how these complex interventions affect patient care and outcomes, particularly in LMIC where there is a paucity of data.

For an integrated approach to improving patient monitoring and follow-up, see Table 6 [106–108].

ADAPTING TO NATIONAL ROADMAPS—FROM PRESCRIBED RECOMMENDATIONS TO PRACTICE IMPLEMENTATION

This Roadmap describes an ideal continuum of care pathway for heart failure, explores the roadblocks along this pathway, and considers potential solutions based on available research and examples in practice. To move from prescribed global recommendations to local and national implementation, a number of specific actions are required to plan, design, and implement change. Previous Roadmaps have outlined steps for adapting suggested frameworks at the national level: multisectorial coalition; situational analyses to consider the national needs, the health care system, and policy environment; policy dialogues to identify and discuss specific barriers and potential strategies; and plan of action to design and implement specific interventions [4]. These steps provide guidance in the development of a call for action for improving heart failure care and reducing the burden of this rising epidemic. This process is well described in previous Roadmap recommendations [1–6].

The WHF implementation toolkit (Figure 6) offers a step-by-step approach to specific action areas and highlights the importance of an integration across multiple care settings. To move from a global Roadmap initiative to a national

call for action to service implementation, strong leadership and integration between sectors is required, including national ministries of health, education, labor, finance, and transport; health care system decision makers; health care professionals; and representatives from industry, patients, carers, and civil society. Bringing key leaders and stakeholders together for national Roundtable discussions to consider a unified heart failure agenda based on national and local needs is considered a necessary first step.

WHF continues to support national and regional societies and Members to raise the profile of heart failure as a priority area, by facilitating national Roundtable stakeholder discussions, national scorecards, and by creating a global network of research, through initiatives such as the WHF Emerging Leaders program, in addition to providing supporting toolkits for implementation and guidance in key actions areas such as advocacy. All WHF initiatives are aimed at supporting national efforts to reduce the growing burden of heart failure.

FINAL CONSIDERATIONS FOR THE FUTURE OF HEART FAILURE PATIENTS

With an estimated 26 million individuals living with heart failure globally [16], the burden of heart failure is felt at every level of health care: for systems and health care workers confronted by greater numbers of ill patients; and for health economies faced with increasing costs associated with heart failure. Social and geographic inequalities add to this burden for those most vulnerable. Despite challenges in the delivery of high-quality care to heart failure patients, there are many examples of successful interventions that have been implemented in various socioeconomic settings that may pave the way for a brighter future for heart failure patients.

This WHF Heart Failure Roadmap offers an outline of an ideal continuum of care pathway for heart failure that is relevant across all countries and regions. Specific roadblocks may differ depending on local context. By raising awareness of heart failure among health care professionals and key stakeholders, addressing the inequities of care to patients with heart failure, highlighting common challenges in the delivery of care globally, and bridging the care gap between knowledge and implementation, this Heart Failure Roadmap provides a platform on which to build services that prioritize patients and improve outcomes for heart failure patients.

ACKNOWLEDGMENTS

The authors would like to thank WHF members for their contribution to the development of this Roadmap. Information gathered was essential to the development of the Roadmap, and the authors thank all those who took the time to complete the survey and send their feedback. The authors also thank the corporate partners for their support




FIGURE 6. Implementation toolkit.

in the development of WHF Roadmaps. The corporate partners supporting the WHF Roadmap Programme include Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Novo Nordisk, Pfizer, and Sanofi. The authors also thank the WHF for its support through the publication development.

REFERENCES

1. Perel P, Avezum A, Huffman M, et al. Reducing premature cardiovascular morbidity and mortality in people with atherosclerotic vascular disease: the World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease. *Glob Heart* 2015;10:99–110.
2. Grainger Gasser A, Welch C, Arora M, et al. Reducing cardiovascular mortality through tobacco control: a World Heart Federation Roadmap. *Glob Heart* 2015;10:123–33.
3. Adler AJ, Prabhakaran D, Bovet P, Kazi DS, Mancia G, Mungai-Singh V, Poulter N. Reducing cardiovascular mortality through prevention and management of raised blood pressure: a World Heart Federation Roadmap. *Glob Heart* 2015;10:111–22.
4. Palafox B, Mocumbi AO, Kumar RK, et al. The WHF Roadmap for Reducing CV Morbidity and Mortality Through Prevention and Control of RHD. *Glob Heart* 2017;12:47–62.
5. Murphy A, Banerjee A, Breithardt G, et al. The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. *Glob Heart* 2017;12:273–84.

6. Murphy A, Faria-Neto JR, Al-Rasadi K, et al. World Heart Federation Cholesterol Roadmap. *Glob Heart* 2017;12:179–97.
7. Diem G, Brownson RC, Grabauskas V, Shatchkute A, Stachenko S. Prevention and control of noncommunicable diseases through evidence-based public health: implementing the NCD 2020 Action Plan. *Glob Health Promot* 2016;23:5–13.
8. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016;18:891–975.
9. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Am Coll Cardiol* 2016;68:1476–88.
10. Andersson C, Vasan RS. Epidemiology of heart failure with preserved ejection fraction. *Heart Fail Clin* 2014;10:377–88.
11. Garbi M, McDonagh T, Cosyns B, et al. Appropriateness criteria for cardiovascular imaging use in heart failure: report of literature review. *Eur Heart J Cardiovasc Imaging* 2015;16:147–53.
12. Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. *Health Technol Assess* 2009;13:1–207.
13. Thomas JT, Kelly RF, Thomas SJ, Stamos TD, Albasha K, Parrillo JE, Calvin JE. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. *Am J Med* 2002;112:437–45.
14. Semantic Health Net. Semantic Interoperability for Health Network: Deliverable 1.1: Specification of Scenarios and Information Flows for Chronic Heart Failure. June 30, 2012. Available at: http://semantichhealthnet.eu/SemanticHealthNet/assets/File/D1_1%20Specification%20of%20scenarios%20and%20information%20flows%20for%20chronic%20heart%20failure.pdf. Accessed June 4, 2019.
15. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. *J Am Coll Cardiol* 2014;63:1123–33.
16. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. *Nat Rev Cardiol* 2016;13:368.
17. Dokainish H, Teo K, Zhu J, et al. Heart failure in Africa, Asia, the Middle East and South America: the INTER-CHF study. *Int J Cardiol* 2016;204:133–41.
18. Alla F, Zannad F, Filippatos G. Epidemiology of acute heart failure syndromes. *Heart Fail Rev* 2007;12:91–5.
19. Zannad F, Agrinier N, Alla F. Heart failure burden and therapy. *Europace* 2009;11:v1–9.
20. Crespo-Leiro MG, Anker SD, Maggioni AP, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. *Eur J Heart Fail* 2016;18:613–25.
21. Lightwood J, Fleischmann KE, Glantz SA. Smoking cessation in heart failure: it is never too late. *J Am Coll Cardiol* 2001;37:1683–4.
22. Damasceno A, Mayosi BM. The Sub-Saharan Africa Survey of Heart Failure (THESUS-HF). *Arch Intern Med* 2012;172:1386–94.
23. Al-Omary MS, Khan AA, Davies AJ, et al. Outcomes following heart failure hospitalization in a regional Australian setting between 2005 and 2014. *ESC Heart Fail* 2018;5:271–8.
24. Evangelista LS, Doering LV, Dracup K. Usefulness of a history of tobacco and alcohol use in predicting multiple heart failure readmissions among veterans. *Am J Cardiol* 2000;86:1339–42.
25. Bryson CL, Mukamal KJ, Mittleman MA, Fried LP, Hirsch CH, Kitzman DW, Siscovick DS. The association of alcohol consumption and incident heart failure: the Cardiovascular Health Study. *J Am Coll Cardiol* 2006;48:305–11.
26. Piepoli MF, Conraads V, Corra U, et al. Exercise training in heart failure: from theory to practice: a consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. *Eur J Heart Fail* 2011;13:347–57.
27. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. *J Am Coll Cardiol* 1993;22(Suppl 1):A6–13.
28. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. *JAMA* 1996;275:1557–62.
29. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. *Heart* 2007;93:1137–46.
30. Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. *Circ Cardiovasc Qual Outcomes* 2017;10:e003497.
31. Davie AP, Francis CM, Love MP, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. *BMJ* 1996;312:222.
32. Hobbs FDR, Davis RK, Lip GYH. Heart failure in general practice. *BMJ* 2000;320:626–9.
33. Attia ZI, Kapa S, Lopez-Jimenez F, et al. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. *Nat Med* 2019;25:70.
34. Zhang J, Gajjala S, Agrawal P, et al. Fully automated echocardiogram interpretation in clinical practice: feasibility and diagnostic accuracy. *Circulation* 2018;138:1623–35.
35. Gheorghide M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. *Circulation* 2005;112:3958–68.
36. Collins SP, Storrow AB. Moving toward comprehensive acute heart failure risk assessment in the emergency department: the importance of self-care and shared decision making. *JACC Heart Fail* 2013;1:273–80.
37. van der Wal MH, Jaarsma T. Adherence in heart failure in the elderly: problem and possible solutions. *Int J Cardiol* 2008;125:203–8.
38. Cajita MI, Gleason KT, Han HR. A systematic review of mHealth-based heart failure interventions. *J Cardiovasc Nurs* 2016;31:E10.
39. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med* 2005;352:1539–49.
40. Pattenden JF, Roberts H, Lewin RJP. Living with heart failure; patient and carer perspectives. *Eur J Cardiovasc Nurs* 2007;6:273–9.
41. Grigaliūnas G, Lycholip E, Burneikaitė G, et al. Heart failure awareness: a cross-sectional study on misconceptions and educational opportunities. *Semin Cardiovasc Med* 2018;24:9–15.
42. Smeets M, Van Roy S, Aertgeerts B, Vermandere M, Vaes B. Improving care for heart failure patients in primary care, GPs' perceptions: a qualitative evidence synthesis. *BMJ Open* 2016;6:e013459.
43. Remme WJ, McMurray JJ, Hobbs FR, et al. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. *Eur Heart J* 2008;29:1739–52.
44. Murray SA, Boyd K, Kendall M, Worth A, Benton TF, Clausen H. Dying of lung cancer or cardiac failure: prospective qualitative interview study of patients and their carers in the community. *BMJ* 2002;325:929.
45. Pumping Marvellous website. Available at: <https://pumpingmarvellous.org/>. Accessed July 1, 2019.
46. Ahmad FS, Barg FK, Bowles KH, et al. Comparing perspectives of patients, caregivers, and clinicians on heart failure management. *J Card Fail* 2016;22:210–7.
47. Heart Failure Policy Network. The Handbook of Multidisciplinary and Integrated Heart Failure Care. Available at: http://www.hfpolicynetwork.eu/wp-content/uploads/2018/09/HFPN_handbookD_DIGITAL.pdf. Accessed May 28, 2019.
48. Remme WJ, McMurray JJ, Rauch B, et al. Public awareness of heart failure in Europe: first results from SHAPE. *Eur Heart J* 2005;26:2413–21.
49. Lainscak M, Letonja M, Kovacic D, et al. General public awareness of heart failure: results of questionnaire survey during Heart Failure Awareness Day 2011. *Arch Med Sci* 2014;10:355–60.

50. Savarese G, Lund LH. Global public health burden of heart failure. *Card Fail Rev* 2017;3:7.
51. Wagenaar KP, Rutten FH, Klompstra L, et al. "heartfailurematters.org," an educational website for patients and carers from the Heart Failure Association of the European Society of Cardiology: objectives, use and future directions. *Eur J Heart Fail* 2017;19:1447–54.
52. Chen MY, Karvelas M, Sundararajan V, Hocking JS, Fairley CK. Evidence for the effectiveness of a chlamydia awareness campaign: increased population rates of chlamydia testing and detection. *Int J STD AIDS* 2007;18:239–43.
53. Jacobsen GD, Jacobsen KH. Health awareness campaigns and diagnosis rates: evidence from National Breast Cancer Awareness Month. *J Health Econ* 2011;30:55–61.
54. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP-HF randomized trial. *JAMA* 2013;310:66–74.
55. Ledwidge MT, O'Connell E, Gallagher J, et al. Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) study. *Eur J Heart Fail* 2015;17:672–9.
56. Gallagher J, Watson C, Campbell P, Ledwidge M, McDonald K. Natriuretic peptide-based screening and prevention of heart failure. *Card Fail Rev* 2017;3:83.
57. Alston L, Nichols M, Allender S. Policy makers' perceptions of the high burden of heart disease in rural Australia: implications for the implementation of evidence-based rural health policy. *PLoS One* 2019;14:e0215358.
58. van de Vijver S, Akinyi H, Oti S, Olajide A, Agyemang C, Aboderin I, Kyobutungi C. Status report on hypertension in Africa—Consultative review for the 6th Session of the African Union Conference of Ministers of Health on NCD's. *Pan Afr Med J* 2013;16:38.
59. Ewald B, Ewald D, Thakkinian A, Attia J. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction. *Int Med J* 2008;38:101–13.
60. Remes J, Miettinen H, Reunanen A, Pyörälä K. Validity of clinical diagnosis of heart failure in primary health care. *Eur Heart J* 1991; 12:315–21.
61. Taylor CJ, Rutten FH, Brouwer JR, Hobbs FR. Practical guidance on heart failure diagnosis and management in primary care: recent EPCCS recommendations. *Br J Gen Pract* 2017;67:326–7.
62. Kelder JC, Cramer MJ, van Wijngaarden J, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. *Circulation* 2011;124:2865–73.
63. Fuat A, Hungin APS, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study. *BMJ* 2003;326:196.
64. Taylor CJ. Diagnosing heart failure: challenges in primary care. *Heart* 2019;105:663–4.
65. de Lemos JA, McGuire DK, Khera A, Das SR, Murphy SA, Omland T, Drazner MH. Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study. *Am Heart J* 2009;157: 746–53.
66. Xanthakis V, Larson MG, Wollert KC, et al. Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening. *J Am Heart Assoc* 2013; 2:e000399.
67. Oh JK. Echocardiography in heart failure: beyond diagnosis. *Eur J Echocardiogr* 2007;8:4–14.
68. Atherton JJ. Chronic heart failure: we are fighting the battle, but are we winning the war? *Scientifica (Cairo)* 2012;2012:279731.
69. Januzzi JL. Natriuretic peptides as biomarkers in heart failure. *J Investig Med* 2013;61:950–5.
70. British Heart Foundation. Focus on Heart Failure Report. 2016. Available at: <https://www.bhf.org.uk/-/media/files/campaigning/appg-on-heart-disease-focus-on-heart-failure-report.pdf>. Accessed June 4, 2019.
71. Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, Stewart S. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. *Lancet* 2008;371:915–22.
72. Damasceno A, Mayosi BM, Sani M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. *Arch Intern Med* 2012;172:1386–94.
73. Kwan GF, Bukhman AK, Miller AC, et al. A simplified echocardiographic strategy for heart failure diagnosis and management within an integrated noncommunicable disease clinic at district hospital level for sub-Saharan Africa. *JACC Heart Fail* 2013;1:230–6.
74. Cowie MR, Anker SD, Cleland JG, et al. Improving care for patients with acute heart failure: before, during and after hospitalization. *ESC Heart Fail* 2014;1:110–45.
75. Parker SM, Stocks N, Nutbeam D, et al. Preventing chronic disease in patients with low health literacy using eHealth and teamwork in primary healthcare: protocol for a cluster randomised controlled trial. *BMJ Open* 2018;8:e023239.
76. Al-Mohammad A, Mant J. The diagnosis and management of chronic heart failure: review following the publication of the NICE guidelines. *Heart* 2011 Mar 1;97:411–1416.
77. Huffman M, Roth G, Sliwa K, Yancy CW, Prabhakaran D. Heart failure. In: Prabhakaran D, Anand S, Gaziano TA, Mbanya JC, Wu Y, Nugent R, editors. *Heart Failure—Cardiovascular, Respiratory, and Related Disorders*. Washington, DC: The International Bank for Reconstruction and Development/The World Bank; 2017. chapter 10.
78. Ponikowski P, Jankowska EA. Pathogenesis and clinical presentation of acute heart failure. *Rev Esp Cardiol (Engl Ed)* 2015;68:331–7.
79. Shah D, Simms K, Barksdale D, Wu JR. Improving medication adherence of patients with chronic heart failure: challenges and solutions. *Res Rep Clin Cardiol* 2015;6:87–95.
80. Ruppert TM, Cooper PS, Mehr DR, Delgado JM, Dunbar-Jacob JM. Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta-analysis of controlled trials. *J Am Heart Assoc* 2016;5:e002606.
81. Wu JR, Moser DK, Chung ML, Lennie TA. Objectively measured, but not self-reported, medication adherence independently predicts event-free survival in patients with heart failure. *J Card Fail* 2008;14:203–10.
82. Plotka A, Prokop E, Migaj J, Straburzyńska—Migaj E, Grajek S. Patients' knowledge of heart failure and their perception of the disease. *Patient Prefer Adherence* 2017;11:1459–67.
83. Calvin JE, Shanbhag S, Avery E, Kane J, Richardson D, Powell L. Adherence to evidence-based guidelines for heart failure in physicians and their patients: lessons from the Heart Failure Adherence Retention Trial (HART). *Congest Heart Fail* 2012;18:73–8.
84. Gattis WA, O'Connor CM, Gallup DS, Hasselblad V, Gheorghade M. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. *J Am Coll Cardiol* 2004;43:1534–41.
85. Maggioni AP, Sinagra G, Opasich C, et al. Treatment of chronic heart failure with β adrenergic blockade beyond controlled clinical trials: the BRING-UP experience. *Heart* 2003;89:299–305.
86. Fonarow GC, Abraham WT, Albert NM, et al. Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and design. *Am Heart J* 2004;148:43–51.
87. Miller CM, Kethapile M, Rybasack-Smith H, Rosen S. Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. *Trop Med Int Health* 2010;15:48–54.
88. Albert NM, Barnason S, Deswal A, et al. Transitions of care in heart failure: a scientific statement from the American Heart Association. *Circ Heart Fail* 2015;8:384–409.
89. Murray MD, Young J, Hoke S, et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. *Ann Intern Med* 2007;146:714–25.
90. López Cabezas C, Falces Salvador C, Cubí Quadrada D, Arnau Bartés A, Ylla Boré M, Perea Wall N, Homs Peipoch E. Randomized clinical trial of a post-discharge pharmaceutical care program vs regular follow-up in patients with heart failure. *Farm Hosp* 2006;30:328–42.

91. Yeates K, Lohfeld L, Sleeth J, Morales F, Rajkotia Y, Ogedegbe O. A global perspective on cardiovascular disease in vulnerable populations. *Can J Cardiol* 2015;31:1081–93.
92. Pillai HS, Ganapathi S. Heart failure in South Asia. *Curr Cardiol Rev* 2013;9:102–11.
93. Soliman EZ, Mendis S, Dissanayake WP, Somasundaram NP, Gunaratne PS, Jayasingne IK, Furberg CD. A polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. *Trials* 2011;12:3.
94. Maciejewski ML, Farley JF, Parker J, Wansink D. Copayment reductions generate greater medication adherence in targeted patients. *Health Aff (Millwood)* 2010;29:2002–8.
95. Klersy C, De Silvestri A, Gabutti G, Regoli F, Auricchio A. A meta-analysis of remote monitoring of heart failure patients. *J Am Coll Cardiol* 2009;54:1683–94.
96. Gattis WA, Hasselblad V, Whella DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. *Arch Intern Med* 1999;159:1939–45.
97. McDonald K, Ledwidge M, Cahill J, et al. Heart failure management: multidisciplinary care has intrinsic benefit above the optimization of medical care. *J Card Fail* 2002;8:142–8.
98. Health Policy Partnership. *The Patient Perspective on Heart Failure Report*. August 2017. Available at: <https://www.keepitpumping.com/globalassets/kip102/life-with-heartfailure/patient-perspective-of-heart-failure/patient-perspective-on-hf-report.pdf>. Accessed June 3, 2017. Accessed.
99. Strömberg A. The crucial role of patient education in heart failure. *Eur J Heart Fail* 2005;7:363–9.
100. Snow R, Humphrey C, Sandall J. What happens when patients know more than their doctors? Experiences of health interactions after diabetes patient education: a qualitative patient-led study. *BMJ Open* 2013;3:e003583.
101. Beagley L. Educating patients: understanding barriers, learning styles, and teaching techniques. *J Perianesth Nurs* 2011;26:331–7.
102. Eames S, Hoffmann T, Worrall L, Read S. Delivery styles and formats for different stroke information topics: patient and carer preferences. *Patient Educ Couns* 2011;84:e18–23.
103. Chan YK, David AM, Mainland C, Chen L, Stewart S. Applying heart failure management to improve health outcomes: but WHICH one? *Card Fail Rev* 2017;3:113.
104. Harris M, Smith BJ, Veale A. Patient education programs—can they improve outcomes in COPD? *Int J Chron Obstruct Pulmon Dis* 2008;3:109.
105. Takeda A, Martin N, Taylor RS, Taylor SJ. Disease management interventions for heart failure. *Cochrane Database Syst Rev* 2019;1:CD002752.
106. Inglis SC, Clark RA, Dierckx R, Prieto-Merino D, Cleland JG. Structured telephone support or non-invasive telemonitoring for patients with heart failure. *Cochrane Database Syst Rev* 2015;10:CD007228.
107. Ayyadurai P, Alkhawam H, Saad M, Al-Sadawi MA, Shah NN, Kosmas CE, Vittorio TJ. An update on the CardioMEMS pulmonary artery pressure sensor. *Ther Adv Cardiovasc Dis* 2019;13:1753944719826826.
108. Wu JR, Corley DJ, Lennie TA, Moser DK. Effect of a medication-taking behavior feedback theory-based intervention on outcomes in patients with heart failure. *J Card Fail* 2012;18:1–9.